<DOC>
	<DOC>NCT02791815</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the effect of repeated doses of selexipag on the pharmacokinetics of a single oral dose of midazolam (i.e., how long and how much midazolam is present in the blood)</brief_summary>
	<brief_title>Potential Pharmacokinetic Interaction Between Selexipag and Midazolam in Healthy Male Subjects</brief_title>
	<detailed_description>In order to exclude an inductive effect of selexipag in the gastrointestinal tract, this study aims at investigating the effect of selexipag on the PK of midazolam, a sensitive substrate of both hepatic and intestinal cytochrome P450 3A4 (CYP3A4).</detailed_description>
	<mesh_term>Selexipag</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Key Signed informed consent form Age from 18 to 45 years (inclusive) at screening Body mass index (BMI) from 18.0 to 28.0 kg/m2 (inclusive) at screening Healthy on the basis of physical examination, cardiovascular assessments and laboratory tests Key Any contraindication to the study treatments History or clinical evidence of any disease or medical / surgical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the absorption, distribution, metabolism or excretion of the study treatments Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>selexipag</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>midazolam</keyword>
</DOC>